Pimodivir

Pimodivir
Clinical data
Trade names	Pimodivir
Legal status
Legal status	US: Investigational New Drug ;
Identifiers
	IUPAC name (2S,3S)-3-[[5-fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]bicyclo[2.2.2]octane-2-carboxylic acid;
CAS Number	1629869-44-8 ;
PubChem CID	67286591 ;
UNII	DFC121MXC3 ;
Chemical and physical data
Formula	C20H19F2N5O2
Molar mass	399.402 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES O=C(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F;
	InChI InChI=1S/C20H19F2N5O2/c21-11-5-12-13(7-24-17(12)23-6-11)18-25-8-14(22)19(27-18)26-16-10-3-1-9(2-4-10)15(16)20(28)29/h5-10,15-16H,1-4H2,(H,23,24)(H,28,29)(H,25,26,27)/t9?,10?,15-,16-/m0/s1; Key:JGPXDNKSIXAZEQ-SBBZOCNPSA-N;

Last updated December 15, 2025

Pimodivir (VX-787, JNJ-63623872) is an antiviral drug which was developed as a treatment for influenza. It acts as an inhibitor of influenza virus polymerase basic protein 2, and has shown promising results in Phase II clinical trials.^[1]^[2]^[3] However, in late 2021, Janssen announced that the clinical development of pimidivir had been halted due to lack of benefit over standard of care.^[4]

References

↑ Trevejo JM, Asmal M, Vingerhoets J, Polo R, Robertson S, Jiang Y, et al. (2018). "Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study". Antiviral Therapy. 23 (4): 335–344. doi:10.3851/IMP3212. PMID 29244026. S2CID 4005581.
↑ Finberg RW, Lanno R, Anderson D, Fleischhackl R, van Duijnhoven W, Kauffman RS, et al. (March 2019). "Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial". The Journal of Infectious Diseases. 219 (7): 1026–1034. doi: 10.1093/infdis/jiy547 . PMID 30428049.
↑ Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC (July 2019). "Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference". Antiviral Research. 167: 45–67. doi:10.1016/j.antiviral.2019.04.006. PMC 7132446 . PMID 30974127.
↑ "Janssen's lead coronavirus vaccine shows preclinical promise". 4 September 2020.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Trevejo JM, Asmal M, Vingerhoets J, Polo R, Robertson S, Jiang Y, et al. (2018). "Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study". Antiviral Therapy. 23 (4): 335–344. doi:10.3851/IMP3212. PMID 29244026. S2CID 4005581.

[2] Finberg RW, Lanno R, Anderson D, Fleischhackl R, van Duijnhoven W, Kauffman RS, et al. (March 2019). "Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial". The Journal of Infectious Diseases. 219 (7): 1026–1034. doi: 10.1093/infdis/jiy547 . PMID 30428049.

[3] Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC (July 2019). "Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference". Antiviral Research. 167: 45–67. doi:10.1016/j.antiviral.2019.04.006. PMC 7132446 . PMID 30974127.

[4] "Janssen's lead coronavirus vaccine shows preclinical promise". 4 September 2020.

[1]

[2]

[3]

[4]

Pimodivir

See also

References